RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cara Therapeutics Stock

Cara Therapeutics Equity 2024

Cara Therapeutics Equity

57.08 M USD

Ticker

CARA

ISIN

US1407551092

WKN

A1XDTK

In 2024, Cara Therapeutics's equity was 57.08 M USD, a -64.05% increase from the 158.8 M USD equity in the previous year.

Cara Therapeutics Aktienanalyse

What does Cara Therapeutics do?

Cara Therapeutics Inc. is a US pharmaceutical company based in Stamford, Connecticut, specializing in the development of novel therapies for the treatment of pain conditions. The company was founded in 2004 by Derek Chalmers and Eric Carter and has been publicly traded on the NASDAQ since its IPO in 2014. Cara Therapeutics Inc.'s history is closely linked to the discovery of adenosine A2A receptor modulation. In recent years, the company has successfully utilized this class of compounds in innovative ways to develop novel pain treatment solutions. The company also has a close collaboration with Yale University and other leading research institutions in the field of neurology and pain research. Cara Therapeutics Inc.'s business model is based on the development and commercialization of new pain therapies, particularly based on Cara - a synthetic adenosine A2A receptor antagonist. The medications developed by Cara Therapeutics Inc. are designed to provide effective pain relief to patients without the strong side effects of traditional pain medications such as opioids. Cara Therapeutics Inc. is divided into several divisions that encompass different areas of the company. These include research and development, production, sales and marketing, as well as the supply chain. The research and development division of Cara Therapeutics Inc. works closely with leading research institutions and scientists to continuously develop new treatment options. The focus is always on the needs of patients and healthcare providers, with an emphasis on advancing treatment options with Cara and other new compounds. The production facilities of Cara Therapeutics Inc. are specialized in the production of Cara-based therapies and aim to ensure high quality and patient access. The company works closely with various partners domestically and internationally to ensure global patient access. The sales and marketing division of Cara Therapeutics Inc. is focused on placing the company's products on the market and communicating the benefits of the offered therapies to patients. The company relies on a global network of distribution partners and close collaboration with healthcare professionals. An important focus of the company is the supply chain - ensuring continuous patient access to necessary medications as well as ensuring compatibility and traceability of treatment options. Some of the most well-known and important products of Cara Therapeutics Inc. include Korsuva, a pain medication developed for the treatment of pruritus in patients with chronic kidney disease on hemodialysis, as well as a wide range of other pain therapies. Overall, Cara Therapeutics Inc. is an innovative company specializing in the treatment of pain conditions and is at the forefront of pain therapy research and development. The company places special emphasis on ensuring that their pain therapies are as effective and safe as possible in order to provide patients with effective pain relief. Cara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Cara Therapeutics's Equity

Cara Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cara Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cara Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cara Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cara Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cara Therapeutics stock

What is the equity of Cara Therapeutics this year?

Cara Therapeutics has equity of 57.08 M USD this year.

What was the equity of Cara Therapeutics compared to the previous year?

The equity of Cara Therapeutics has increased/decreased by -64.05% decreased compared to the previous year.

What impact does a high equity have on investors of Cara Therapeutics?

A high equity is advantageous for investors of Cara Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Cara Therapeutics?

A low equity can be a risk for investors of Cara Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Cara Therapeutics affect the company?

An increase in equity of Cara Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Cara Therapeutics affect the company?

A reduction in equity of Cara Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Cara Therapeutics?

Some factors that can affect the equity of Cara Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Cara Therapeutics so important for investors?

The equity of Cara Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Cara Therapeutics take to change the equity?

To change equity, Cara Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Cara Therapeutics pay?

Over the past 12 months, Cara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cara Therapeutics?

The current dividend yield of Cara Therapeutics is .

When does Cara Therapeutics pay dividends?

Cara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cara Therapeutics?

Cara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cara Therapeutics located?

Cara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cara Therapeutics from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Cara Therapeutics pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Cara Therapeutics in the year 2023?

In the year 2023, Cara Therapeutics distributed 0 USD as dividends.

In which currency does Cara Therapeutics pay out the dividend?

The dividends of Cara Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cara Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cara Therapeutics

Our stock analysis for Cara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.